Whole-genome association studies in rheumatoid arthritis have identified single-nucleotide polymorphisms (SNPs) predisposing to disease with moderate risk. We aimed to investigate the role of these markers in predicting methotrexate (MTX) response, measured by continuation on MTX monotherapy in patients with recent onset inflammatory polyarthritis (IP). In all, 19 SNPs were genotyped in 736 patients treated with MTX following registration, or not more than 3 months before registration, to the Norfolk Arthritis Register. The association of SNPs with MTX continuation by year 1 and by year 2 was investigated using Cox proportional hazard regression models. A SNP within the OLIG3/TNFAIP3 locus (rs6920220) was associated with being less likely to maintain MTX monotherapy at year 1, hazards ratio (HR) 1.73 (1.18, 2.52) and year 2, HR 1.49 (1.11, 2.00); correlating with an increased in adverse events. Weak evidence for an effect at the PTPN22 locus was also observed. These findings require replication in other large datasets.
Introduction
Persistent inflammatory polyarthritis (IP) is a chronic autoimmune disease, characterized by synovial inflammation and associated with progressive joint damage, along with extra-articular manifestations. The majority of cases ultimately satisfy classification criteria for rheumatoid arthritis (RA), which affects 0.8% of the UK adult population.
1 Methotrexate (MTX) is now the drug of first choice in the majority of patients with early IP judged to require disease modifying anti-rheumatic drug (DMARD) therapy. 2 However, efficacy of MTX in IP is variable, 3, 4 and this, alongside an excess risk of toxicity, results in discontinuation of therapy in 10-30% of IP patients. 5 Ideally physicians would like to identify which patients are likely to respond to treatment with MTX without experiencing adverse events but there are currently no reliable clinical or molecular markers of MTX outcome. Recently, a number of pharmacogenomic studies have reported that single-nucleotide polymorphisms (SNPs) within the MTX transporter, 6, 7 folate 8, 9 and adenosine pathway 10, 11 genes may be associated with MTX response thus suggesting that genetic predictors may be identified that could eventually prove useful in a clinical setting. Studies in a number of complex diseases have identified genetic susceptibility factors that are either a target of or predict response to drugs used in the treatment of that condition. For example, the fusion protein abatacept, successful in the treatment of RA, 12 includes the extracellular domain of cytotoxic T-lymphocyte antigen (CTLA)-4-a gene previously associated with RA susceptibility; 13 and variants of transcription factor 7-like 2 (TCF7L2) predict susceptibility to, and response to sulfonylureas in, type two diabetes mellitus. 14 We have previously shown that the major RA susceptibility locus HLA-DRB1 (shared epitope) 15 is a poor predictor of MTX failure overall in early IP. 16 However, the utility of HLA-SE in predicting MTX outcome remains uncertain as previous investigations of this locus have generated conflicting results. 16, 17 More recently a number of non-human leukocyte antigen (HLA) RA susceptibility loci have been identified through large scale genomewide and case control association studies. 18, 19, 13, [20] [21] [22] [23] [24] [25] [26] [27] Many of these loci map to genomic intervals that include genes involved in the immune regulation. In RA, MTX is thought regulate immune responses by inhibiting T-cell proliferation. We hypothesized that recently identified genetic susceptibility markers may also influence MTX treatment outcome. Therefore, in a large primary-care-based inception cohort of patients with recent onset IP, we examined the relationship of newly identified RA SNP susceptibility markers with treatment efficacy measured as continuation on MTX monotherapy at 1 and 2 years following commencement of treatment.
Materials and methods

Subjects
The Norfolk Arthritis Register is a primary-care-based inception cohort of patients with recent onset IP, which has been described in detail elsewhere. 28 In brief patients aged 16 or over at symptom onset, who had synovitis of two or more joints, lasting 4 or more weeks, and whose symptom onset was after 1 January 1990, were recruited from general practitioners and rheumatologists in the catchment area formerly covered by the Norwich Health Authority. Ethical approval was given by the Norwich Research Ethics Committee, and all participants gave informed consent (LREC 2003-075) . Clinical, demographic and treatment data were collected at baseline and annual follow-up by a research nurse via a structured interview and clinical examination. In addition, DNA and serum samples were collected at baseline. Anti-citrullinated peptide/protein antibody (ACPA) was measured using the CCP2 detection kit (positivity X5 U ml À1 ; Axis-Shield, Cambridgeshire, UK). Patients who received a clinical diagnosis other than RA or IP at baseline assessment or subsequent follow-up were excluded from the study.
Genotyping
In all, 19 SNPs were selected for genotyping using Sequenom MassArray technology according to the manufacturer's instructions, using iPLEX chemistry (http://www.sequenom.com). The SNPs were markers associated with RA susceptibility in cohorts tested by our group and others and consisted of: rs1160542 (AFF3), rs2812378 (CCL21), rs763361 (CD226), rs4810485 (CD40), rs3087243 and rs231775 (CTLA4), rs6822844 (IL2/IL21), rs2104286 (IL2RA), rs743777 (IL2RB), rs6897932 (IL7RA), rs1678542 (KIF5A), rs4750316 (PRKCQ), rs7574865 (STAT4), rs13207033, rs5029937 and rs6920220 (6q23), rs10760130 and rs2900180 (TRAF1/C5) and rs2476601 (PTPN22). 13, 18, 19, [20] [21] [22] [23] [24] [25] [26] [27] Only those SNPs with a genotype success rate of 495% were included in the analysis.
Statistical analysis
The association of SNP markers with MTX continuation was assessed using Cox proportional hazard regression models after adjusting for symptom duration, age at registration and gender. Each subject entered the analysis on their symptom onset date and became at risk of MTX failure on the date when treatment with MTX first commenced. Treatment continuation, that is, remaining on MTX monotherapy by year 1 and year 2 following first exposure to MTX was investigated. Patients were deemed to have failed MTX treatment if they discontinued treatment because of an adverse event or inefficacy, or if monotherapy with MTX was replaced by combination therapy including a second DMARD.
The subgroup of patients who satisfied the American College of Rheumatology criteria for RA 29 within 5 years from inclusion in Norfolk Arthritis Register was then analysed separately. 30 All statistical analyses were conducted using Stata version 9 (http://www.StataCorp.com).
Results
Study population characteristics
In all, 908 IP patients, recruited between 1990-2004, were treated with MTX after recruitment or not more than 3 months before recruitment to Norfolk Arthritis Register. A total of 41 patients had either a missing symptom onset or MTX start date and were excluded from the study. Of the remaining patients, DNA was available for 736. Following genotyping quality control, 713 samples remained (97% success). In all, 17 patients were removed from the study for stopping MTX treatment through lack of compliance. The characteristics of the remaining 696 patients are summarized in Table 1 . In all, 84% of these IP patients went on to satisfy American College of Rheumatology criteria for RA within 5 years of follow-up.
MTX monotherapy continuation analysis
Only 2 of the 19 SNPs tested showed evidence of association with MTX continuation. The SNP, rs6920220, maps to the genomic interval flanked by the OLIG3 and TNFAIP3 genes OLIG3/TNFAIP3 associates with methotrexate outcome D Plant et al on chromosome 6q and has been associated with susceptibility to RA in multiple populations. 31, 32, 26 Carriage of the RA susceptibility allele of marker rs6920220 (OLIG3/ TNFAIP3) was associated with being less likely to maintain MTX-monotherapy treatment by year 1 and year 2, in both IP and the sub-group of patients who satisfied American College of Rheumatology criteria (year 1: IP hazards ratio (HR) 1.73 (1.18-2.52); RA HR 1.76 (1.17-2.65)); (year 2: IP HR 1.49 (1.11-2.00); RA HR 1.53 (1.11-2.09); Table 2 ).
An association was observed for the SNP marker rs2476601 (PTPN22). Carriage of two copies of the RA susceptibility allele at this locus was associated with being less likely to maintain MTX as a monotherapy (year 1: IP HR 2.99 (1.28-6.97); RA HR 4.39 (1.85-10.41)); (year 2: IP HR 3.32 (1.67-6.60); RA HR 4.65 (2.21-9.78); Table 2 ).
Discussion
Substantial recent progress has been made in identifying genetic variants that predispose to RA susceptibility, and many are involved in immune regulation and inflammation. 21, 33 For instance, the recently identified candidate loci STAT4
19 is a transcription factor that directs CD4 restricted T-cells toward proinflammatory T-helper lineages; 34 and TRAF1 31 functions in signalling pathways important for T cell proliferation and differentiation. 33 In patients with RA, MTX is thought to act through inhibition of T cell proliferation. 35 We therefore hypothesized that genetic susceptibility markers may also be important predictors of MTX outcome. We report that the RA susceptibility allele of the SNP marker rs6920220 (OLIG3/TNFAIP3) was associated with being less likely to maintain MTX monotherapy by year 1 and year 2, in both IP and RA (Table 2) . This association is, however, modest.
In all, 19 SNPs mapping to 14 loci were assessed for association with MTX continuation resulting in multiple testing and the consequent potential of generating false positive results. After applying a conservative Bonferroni correction for 19 tests, rs6920220 was no longer significantly correlated with MTX continuation at the corrected threshold. Furthermore, in this study the effect seen at the rs6920220 SNP locus in patients homozygous for the risk allele was observed to be lower than that observed for heterozygotes, albeit with considerable overlap in the confidence intervals. Although the effect at this locus is consistent with a dominant model, this pattern perhaps reflects the small number of observations in the homozygous patient group (Table 2) . However, the fact that the variant was associated with MTX continuation at both years 1 and 2, with the effect in the same direction, lends support that this may represent a true finding. The rs2476601 marker did retain statistically significant evidence for association with MTX continuation at the corrected threshold at year 2 and in the IP and RA sub-group (Table 2) ; however the association at this locus is based on an extremely small stratum of patients who carry two copies of the RA susceptibility allele (n ¼ 9 individuals; Table 2 ). There is only weak evidence of an effect at either OLIG3/ TNFAIP3 or PTPN22; therefore replication in other cohorts is essential before either marker can be recognised as predictive of MTX outcome.
To investigate the reason for failure to maintain MTX monotherapy, patients were sub-divided into groups who failed treatment due to either inefficacy of adverse event (Supplementary Tables 2 and 3 ). These analyses revealed that carriage of two copies of the RA susceptibility risk allele at the rs2476601 locus was predictive of failure to maintain MTX monotherapy because of the inefficacy (Supplementary Table 3 ). In contrast, carriage of the RA susceptibility risk allele at the rs6920220 locus predicted failure to maintain MTX monotherapy because of the adverse event (Supplementary Table 2 ). The effect size for the association between the rs6920220 SNP and failure to maintain MTX monotherapy in the unstratified (Table 2 ) and stratified patient groups (Supplementary Tables 2 and 3 ) was qualitatively similar, however, the association was no longer significant in the smallest patient group tested (inefficacy, n ¼ 618), reflecting lower power when investigating this stratum of patients.
The OLIG3/TNFAIP3 locus has previously been reported to be associated with an increased rate of joint destruction in RA (with the SNP rs9376293; r 2 ¼ 1 with rs6920220) 36 suggesting that it may influence severity as well as susceptibility. Patients with more severe disease might be expected to respond less well to a particular treatment. To assess whether disease severity correlated with MTX monotherapy failure; we investigated ACPA positivity, as a marker of disease severity, in the prediction of MTX monotherapy continuation, but found no association. ACPA positivity was not predictive of MTX continuation within either the 1-or 2-year-time frame (Supplementary Table 1 ). Although ACPA positivity did not predict MTX monotherapy continuation, Measurements were available for 632 patients.
OLIG3/TNFAIP3 associates with methotrexate outcome D Plant et al many genetic markers of RA development seem to be restricted to the subgroup of patients who are positive for these antibodies. We therefore investigated the association of genetic markers with MTX continuation in the ACPA positive sub-group of patients but found no qualitative difference in results compared with the unstratified dataset (data not shown). The SNP rs6920220 lies in the intergenic region between the OLIG3 and TNFAIP3 genes on chromosome 6q. TNFAIP3 functions as a negative regulator of nuclear factor-kB, 37 a transcription factor that regulates the proinflammatory response of tumour necrosis factor (TNF), by inhibiting signalling upstream of kB kinase (IKK). 38 MTX suppresses nuclear factor-kB activation through inhibition of phosphorylation and degradation of IkBa (an inhibitor that sequesters nuclear factor-kB) by IKK. 39 As both TNFAIP3 and MTX are potent attenuators of the TNF-nuclear factor-kB axis, TNFAIP3 represents a very attractive candidate locus in studies of MTX outcome in RA. It is tempting to speculate that a lack of regulation of TNFAIP3 in stimulated T-cells could augment IKK activity, even in the presence of MTX. So far, however, the functional relevance of the reported polymorphism at the OLIG3/TNFAIP3 intergenic region remains unknown. 36 Three SNP markers have previously been associated with RA susceptibility at the 6q23 locus (that is, rs13207033, rs6920220 and rs5029937). 40 All three markers were tested for correlation with MTX continuation in this study, but no association was observed for the rs13207033 or rs5029937 SNP markers (Supplementary Table 1 ). This is entirely plausible given the independence of association with RA susceptibility for the three SNPs. 40 Failure to detect associations with the remaining susceptibility loci tested may reflect inadequate power. We had 80% power (at the 5% significance threshold) to detect a HR of 1.7 and 1.5, assuming 17 and 27% MTX failures in keeping with those observed at year 1 and year 2, respectively ( Table 1 ). The study therefore had limited power to detect modest effects because of the limited sample size, particularly for the sub-groups analysed. In addition, for many of the loci tested, the causal variants have not yet been identified further reducing the power to detect anything but large effects. To achieve 95% power, this study would have required B1200 patients assuming similar MTX failure rates.
Alternatively, the failure to detect association of MTX response with the other RA susceptibility loci may be a true negative finding as it is likely that many markers of treatment response will differ from those conferring disease susceptibility. For example, in pharmacogenetic studies of warfarin efficacy, the major treatment response effects were observed in genes involved in the drug metabolism pathways 41 and previous studies of MTX response in RA Our study has some limitations that require discussion. First, in order to avoid false negatives no correction for multiple testing was applied. The association at the rs6920220 marker with MTX continuation could therefore reflect a false-positive finding. Second, 383 patients in this study received DMARD treatment prior to first commencement with MTX. For example, 318 patients previously received treatment with sulphasalazine and 367 patients received treatment with sulphasalazine and/or steroids. There is a potential for bias when looking at one DMARD in isolation as patients may tend to remain on their first DMARD longer than on subsequent treatments.
In summary, these data identify PTPN22 and the OLIG3/TNFAIP3 region on chromosome 6q23 that correlate with MTX monotherapy continuation in patients with IP and RA. Replication of these findings in other cohorts is required to confirm the association but the variance in response accounted for by these SNPs is not sufficiently large to be useful clinically at present. As knowledge of genetic factors affecting MTX response increases, genotyping at this locus may prove useful in combination with other factors.
